Browse GPC3

Summary
SymbolGPC3
Nameglypican 3
Aliases OCI-5; SGBS; SGBS1; SGB; DGSX; glypican proteoglycan 3; SDYS; GTR2-2; MXR7; heparan sulphate proteoglycan; i ......
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor, GPI-anchor Extracellular side ; SUBCELLULAR LOCATION: Secreted glypican-3: Secreted, extracellular space
Domain PF01153 Glypican
Function

Cell surface proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001523 retinoid metabolic process
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001657 ureteric bud development
GO:0001658 branching involved in ureteric bud morphogenesis
GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0001763 morphogenesis of a branching structure
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0003002 regionalization
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006720 isoprenoid metabolic process
GO:0006721 terpenoid metabolic process
GO:0007164 establishment of tissue polarity
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007224 smoothened signaling pathway
GO:0007389 pattern specification process
GO:0007507 heart development
GO:0008589 regulation of smoothened signaling pathway
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0009798 axis specification
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0009948 anterior/posterior axis specification
GO:0009952 anterior/posterior pattern specification
GO:0010171 body morphogenesis
GO:0010463 mesenchymal cell proliferation
GO:0010466 negative regulation of peptidase activity
GO:0010827 regulation of glucose transport
GO:0010828 positive regulation of glucose transport
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0016055 Wnt signaling pathway
GO:0016101 diterpenoid metabolic process
GO:0030099 myeloid cell differentiation
GO:0030100 regulation of endocytosis
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030203 glycosaminoglycan metabolic process
GO:0030282 bone mineralization
GO:0030316 osteoclast differentiation
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030326 embryonic limb morphogenesis
GO:0030509 BMP signaling pathway
GO:0030510 regulation of BMP signaling pathway
GO:0030513 positive regulation of BMP signaling pathway
GO:0031214 biomineral tissue development
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035116 embryonic hindlimb morphogenesis
GO:0035137 hindlimb morphogenesis
GO:0035239 tube morphogenesis
GO:0035567 non-canonical Wnt signaling pathway
GO:0042176 regulation of protein catabolic process
GO:0045732 positive regulation of protein catabolic process
GO:0045807 positive regulation of endocytosis
GO:0045861 negative regulation of proteolysis
GO:0045879 negative regulation of smoothened signaling pathway
GO:0045880 positive regulation of smoothened signaling pathway
GO:0045926 negative regulation of growth
GO:0046323 glucose import
GO:0046324 regulation of glucose import
GO:0046326 positive regulation of glucose import
GO:0048736 appendage development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0060070 canonical Wnt signaling pathway
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060173 limb development
GO:0060541 respiratory system development
GO:0060562 epithelial tube morphogenesis
GO:0060627 regulation of vesicle-mediated transport
GO:0060675 ureteric bud morphogenesis
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0060976 coronary vasculature development
GO:0060993 kidney morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061209 cell proliferation involved in mesonephros development
GO:0061326 renal tubule development
GO:0061333 renal tubule morphogenesis
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072028 nephron morphogenesis
GO:0072073 kidney epithelium development
GO:0072078 nephron tubule morphogenesis
GO:0072080 nephron tubule development
GO:0072088 nephron epithelium morphogenesis
GO:0072111 cell proliferation involved in kidney development
GO:0072138 mesenchymal cell proliferation involved in ureteric bud development
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0072171 mesonephric tubule morphogenesis
GO:0072176 nephric duct development
GO:0072177 mesonephric duct development
GO:0072178 nephric duct morphogenesis
GO:0072180 mesonephric duct morphogenesis
GO:0072203 cell proliferation involved in metanephros development
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090175 regulation of establishment of planar polarity
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0198738 cell-cell signaling by wnt
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
GO:2000050 regulation of non-canonical Wnt signaling pathway
GO:2000052 positive regulation of non-canonical Wnt signaling pathway
GO:2000095 regulation of Wnt signaling pathway, planar cell polarity pathway
GO:2000096 positive regulation of Wnt signaling pathway, planar cell polarity pathway
Molecular Function GO:0001948 glycoprotein binding
GO:0004857 enzyme inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0043394 proteoglycan binding
GO:0043395 heparan sulfate proteoglycan binding
GO:0060422 peptidyl-dipeptidase inhibitor activity
GO:0061134 peptidase regulator activity
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005775 vacuolar lumen
GO:0005796 Golgi lumen
GO:0031225 anchored component of membrane
GO:0043202 lysosomal lumen
GO:0046658 anchored component of plasma membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis
R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-4420332: Defective B3GALT6 causes EDSP2 and SEMDJL1
R-HSA-3560801: Defective B3GAT3 causes JDSSDHD
R-HSA-3560783: Defective B4GALT7 causes EDS, progeroid type
R-HSA-3656253: Defective EXT1 causes exostoses 1, TRPS2 and CHDS
R-HSA-3656237: Defective EXT2 causes exostoses 2
R-HSA-1643685: Disease
R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism
R-HSA-3781865: Diseases of glycosylation
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2022928: HS-GAG biosynthesis
R-HSA-2024096: HS-GAG degradation
R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-6806667: Metabolism of fat-soluble vitamins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-975634: Retinoid metabolism and transport
R-HSA-162582: Signal Transduction
R-HSA-2187338: Visual phototransduction
Summary
SymbolGPC3
Nameglypican 3
Aliases OCI-5; SGBS; SGBS1; SGB; DGSX; glypican proteoglycan 3; SDYS; GTR2-2; MXR7; heparan sulphate proteoglycan; i ......
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GPC3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between GPC3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16489048Melanoma; hepatocellular carcinomaPromote immunity (T cell function); essential for immunotherapyEmbryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. The depletion experiments and immunohistochemical analyses suggest that both CD8+ and CD4+ T cells contributed to the observed antitumor effect. Human dendritic cells expressing glypican-3 would be a promising means for therapy of melanoma and hepatocellular carcinoma.
28865999Hepatocellular CarcinomaInhibit immunity; candidate for immunotherapy targetGlypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored glycoprotein that is overexpressed in most HCC tissues but not in normal tissues. Here, in C57/B6 mice, we demonstrated that intravenous infusion of GPC3-coupled lymphocytes (LC/GPC3+) elicited robust GPC3-specific antibody and CTL responses, which effectively restricted proliferation and lysed cultured-HCC cells. Administration of LC/GPC3+induced elevated levels of the cytotoxic T cell bioactive factors tumor necrosis factor alpha (TNF-α), interferon-γ (IFN-γ), granzyme B, and perforin, and substantially increased the number of infiltrating CD8+T cells in tumor tissues.
28621802Hepatocellular CarcinomaInhibit immunityHowever, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis. Mechanistic studies have revealed that GPC3 functions in HCC progression by binding to molecules such as Wnt signaling proteins and growth factors.
Summary
SymbolGPC3
Nameglypican 3
Aliases OCI-5; SGBS; SGBS1; SGB; DGSX; glypican proteoglycan 3; SDYS; GTR2-2; MXR7; heparan sulphate proteoglycan; i ......
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GPC3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGPC3
Nameglypican 3
Aliases OCI-5; SGBS; SGBS1; SGB; DGSX; glypican proteoglycan 3; SDYS; GTR2-2; MXR7; heparan sulphate proteoglycan; i ......
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GPC3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.4840.00405
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.2240.0551
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9530.361
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3530.417
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.030.981
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8430.549
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6030.295
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8010.495
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4380.723
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6240.614
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8270.244
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1170.66
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GPC3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277305.5-5.50.572
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275906.8-6.80.304
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGPC3
Nameglypican 3
Aliases OCI-5; SGBS; SGBS1; SGB; DGSX; glypican proteoglycan 3; SDYS; GTR2-2; MXR7; heparan sulphate proteoglycan; i ......
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GPC3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGPC3
Nameglypican 3
Aliases OCI-5; SGBS; SGBS1; SGB; DGSX; glypican proteoglycan 3; SDYS; GTR2-2; MXR7; heparan sulphate proteoglycan; i ......
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GPC3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GPC3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGPC3
Nameglypican 3
Aliases OCI-5; SGBS; SGBS1; SGB; DGSX; glypican proteoglycan 3; SDYS; GTR2-2; MXR7; heparan sulphate proteoglycan; i ......
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GPC3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGPC3
Nameglypican 3
Aliases OCI-5; SGBS; SGBS1; SGB; DGSX; glypican proteoglycan 3; SDYS; GTR2-2; MXR7; heparan sulphate proteoglycan; i ......
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GPC3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGPC3
Nameglypican 3
Aliases OCI-5; SGBS; SGBS1; SGB; DGSX; glypican proteoglycan 3; SDYS; GTR2-2; MXR7; heparan sulphate proteoglycan; i ......
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GPC3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGPC3
Nameglypican 3
Aliases OCI-5; SGBS; SGBS1; SGB; DGSX; glypican proteoglycan 3; SDYS; GTR2-2; MXR7; heparan sulphate proteoglycan; i ......
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GPC3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.